title: [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
authors.forename: A
authors.initials: A
authors.lastname: Palacios Abufón
authors.forename: E
authors.initials: E
authors.lastname: Acebo Mariñas
authors.forename: J
authors.initials: J
authors.lastname: Gardeazabal García
authors.forename: J C
authors.initials: JC
authors.lastname: García-Ruiz
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005153:Facial Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D013156:Splenectomy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone